CLA Stock Overview
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Akari Therapeutics, Plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.04 |
| 52 Week High | US$4.64 |
| 52 Week Low | US$0.94 |
| Beta | 0.96 |
| 1 Month Change | -33.33% |
| 3 Month Change | -56.30% |
| 1 Year Change | -68.10% |
| 3 Year Change | -97.17% |
| 5 Year Change | -98.26% |
| Change since IPO | -99.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| CLA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.0% | -3.1% | 1.8% |
| 1Y | -68.1% | -22.4% | 2.2% |
Return vs Industry: CLA underperformed the German Biotechs industry which returned -22.4% over the past year.
Return vs Market: CLA underperformed the German Market which returned 2.2% over the past year.
Price Volatility
| CLA volatility | |
|---|---|
| CLA Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CLA's share price has been volatile over the past 3 months.
Volatility Over Time: CLA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 11 | Rachelle Jacques | www.akaritx.com |
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.
Akari Therapeutics, Plc Fundamentals Summary
| CLA fundamental statistics | |
|---|---|
| Market cap | €8.96m |
| Earnings (TTM) | -€9.35m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs CLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.01m |
| Earnings | -US$10.01m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CLA perform over the long term?
See historical performance and comparison